955039-52-8Relevant academic research and scientific papers
Discovery of 4-{1-[({1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl}carbonyl) amino]cyclopropyl}benzoic acid (MF-766), a highly potent and selective EP 4 antagonist for treating inflammatory pain
Colucci, John,Boyd, Michael,Berthelette, Carl,Chiasson, Jean-Francois,Wang, Zhaoyin,Ducharme, Yves,Friesen, Rick,Wrona, Mark,Levesque, Jean-Francois,Denis, Danielle,Mathieu, Marie-Claude,Stocco, Rino,Therien, Alex G.,Clarke, Patsy,Rowland, Steve,Xu, Daigen,Han, Yongxin
scheme or table, p. 3760 - 3763 (2010/09/03)
The discovery of a highly potent and selective EP4 antagonist MF-766 is discussed. This N-benzyl indole derivative exhibits good pharmacokinetic profile and unprecedented in vivo potency in the rat AIA model.
INDOLE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
-
Page/Page column 22-23, (2008/06/13)
The invention is directed to indole amide derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.
